NBTX
NanobiotixNBTX
NBTX
About: Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Employees: 108
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
80% more funds holding
Funds holding: 10 [Q3] → 18 (+8) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0.74% less ownership
Funds ownership: 13.62% [Q3] → 12.87% (-0.74%) [Q4]
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
53% less capital invested
Capital invested by funds: $36.9M [Q3] → $17.4M (-$19.5M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
118%
upside
Avg. target
$8
118%
upside
High target
$8
118%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Michael Schmidt 34% 1-year accuracy 15 / 44 met price target | 118%upside $8 | Buy Maintained | 4 Apr 2025 |
Financial journalist opinion
Based on 3 articles about NBTX published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:
Neutral
GlobeNewsWire
1 week ago
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached] Median Local Progression-Free Survival of 13.3 months from completion of radiation Notable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OS CA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurrent chemotherapy (capecitabine or 5-FU) to radiotherapy-activated JNJ-1900 (NBTXR3) and recruitment is ongoing Investigators concluded that these results support further evaluation in a randomized study Data presented at the 2025 Annual Meeting of the European Society of Radiation Oncology PARIS and CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering nanotherapeutic approaches to improve treatment outcomes for patients with cancer, today announced the presentation of full results from the completed dose escalation and dose expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer.
Neutral
GlobeNewsWire
2 weeks ago
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center, will be presented by principal investigator Dr. Eugene Koay on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CEST during the 2025 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO 2025).
Neutral
Seeking Alpha
1 month ago
Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript
Nanobiotix S.A. (NASDAQ:NBTX ) Q4 2024 Results Conference Call April 3, 2025 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief Executive Officer Bart Van Rhijn - Chief Financial and Business Officer Conference Call Participants Yen-Der Li - Leerink Partners Shan Hama - Jefferies Michael Schmidt - Guggenheim Securities Art He - HCW David Dai - UBS Operator Good day, and welcome to the Nanobiotix Business Update and Full Year 2024 Financial Results Conference Call.
Neutral
GlobeNewsWire
1 month ago
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launched Cash runway extended into mid-2026 and reduction of operational cash burn expected beyond mid-2026 with €49.7 million in cash and cash equivalents as of December 31, 2024 Clinical data readouts in 2025 from Phase 1 and 2 studies in RM-HNSCC, pancreatic cancer, NSCLC amenable to re-irradiation, melanoma and esophageal cancer Conference call and webcast scheduled for April 3, 2025 at 8:00 A.M. EDT / 2:00 P.M.
Neutral
GlobeNewsWire
1 month ago
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST
Neutral
GlobeNewsWire
1 month ago
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the first data from the completed dose escalation part of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center ("MD Anderson") evaluating radiotherapy-activated NBTXR3 (JNJ-1900)1 as a second or later line (2L+) therapy for patients with locally advanced non-small cell lung cancer (“NSCLC”) amenable to re-irradiation. These data will be presented at the 2025 European Lung Cancer Conference by study principal investigator Dr. Saumil Gandhi.
Neutral
GlobeNewsWire
1 month ago
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
PARIS and CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced poster presentations from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) for patients with lung cancer (NSCLC) to be presented at the 2025 European Lung Cancer Conference (“ELCC”).
Neutral
GlobeNewsWire
1 month ago
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET
Neutral
GlobeNewsWire
3 months ago
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conferences:
Charts implemented using Lightweight Charts™